Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Mikrobiologi inom det medicinska området) >
Lot-to-lot immunoge...
-
Ferguson, MurdoColchester Research Group, Canada,Colchester Res Grp, Truro, NS B2N 1L2, Canada.
(författare)
Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults
- Artikel/kapitelEngelska2024
Förlag, utgivningsår, omfång ...
-
Elsevier,2024
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:bth-26212
-
https://urn.kb.se/resolve?urn=urn:nbn:se:bth-26212URI
-
https://doi.org/10.1016/j.jvacx.2024.100494DOI
-
https://lup.lub.lu.se/record/29ffab4a-56ce-48de-bb98-8912cd79fa75URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-532544URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Previous phase 3 studies showed that the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is well tolerated and efficacious in preventing RSV-associated lower respiratory tract disease in adults ≥ 60 years of age. This study evaluated lot-to-lot immunogenicity consistency, reactogenicity, and safety of three RSVPreF3 OA lots. Methods: This phase 3, multicenter, double-blind study randomized (1:1:1) participants ≥ 60 years of age to receive one of three RSVPreF3 OA lots. Serum RSVPreF3-binding immunoglobulin G (IgG) concentration was assessed at baseline and 30 days post-vaccination. Lot-to-lot consistency was demonstrated if the two-sided 95 % confidence intervals (CIs) of the RSVPreF3-binding IgG geometric mean concentration (GMC) ratios between each lot pair at 30 days post-vaccination were within 0.67 and 1.50. Solicited adverse events (AEs) within four days, unsolicited AEs within 30 days, and serious AEs (SAEs) and potential immune-mediated diseases within six months post-vaccination were recorded. Results: A total of 757 participants received RSVPreF3 OA, of whom 708 were included in the per-protocol set (234, 237, and 237 participants for each lot). Lot-to-lot consistency was demonstrated: GMC ratios were 1.06 (95 % CI: 0.94–1.21), 0.92 (0.81–1.04), and 0.87 (0.77–0.99) between the lot pairs (lot 1/2; 1/3; 2/3). For the three lots, the RSVPreF3-binding IgG concentration increased 11.84-, 11.29-, and 12.46-fold post-vaccination compared to baseline. The reporting rates of solicited and unsolicited AEs, SAEs, and potential immune-mediated diseases were balanced between lots. Twenty-one participants reported SAEs; one of these–a case of atrial fibrillation–was considered by the investigator as vaccine-related. SAEs with a fatal outcome were reported for four participants, none of which were considered by the investigator as vaccine-related. Conclusion: This study demonstrated lot-to-lot immunogenicity consistency of three RSVPreF3 OA vaccine lots and indicated that the vaccine had an acceptable safety profile. ClinicalTrials.gov: NCT05059301. © 2024 GSK
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Murray, AlexanderPharmQuest, 806 Green Valley Rd Ste 305, Greensboro, NC 27408 USA.
(författare)
-
Pliamm, LewCanadian Phase Onward Inc, Polyclin Family & Specialty Med Facil, Polyclin Family Hlth Grp, 2 Champagne Dr, Toronto, ON M3J 0K2, Canada.
(författare)
-
Rombo, LarsUppsala universitet,Uppsala University,Centrum för klinisk forskning i Sörmland (CKFD),Institutionen för medicinsk biokemi och mikrobiologi,Clinical Research Centre Sörmland(Swepub:uu)larra728
(författare)
-
Sanmartin Berglund, Johan,ProfessorBlekinge Institute of Technology,Lund University,Lunds universitet,Blekinge Tekniska Högskola,Institutionen för hälsa,Geriatrik,Forskargrupper vid Lunds universitet,Geriatric Medicine,Lund University Research Groups,Geriatrics,Blekinge Inst Technol, Dept Hlth, Valhallavagen 1, SE-37179 Karlskrona, Sweden.;Lund Univ, Dept Clin Sci, BMC I12, SE-22184 Lund, Sweden.(Swepub:lu)smi-jbe
(författare)
-
David, Marie-PierreGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA
(författare)
-
De Schrevel, NathalieGSK, Rue Inst 89, B-1330 Rixensart, Belgium.,GlaxoSmithKline Pharmaceuticals SA
(författare)
-
Maschino, FranckGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA
(författare)
-
Kotb, ShadyGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA
(författare)
-
Olivier, AurélieGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA
(författare)
-
Hulstrøm, VeronicaGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA
(författare)
-
Colchester Research Group, CanadaColchester Res Grp, Truro, NS B2N 1L2, Canada.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Vaccine: X: Elsevier182590-1362
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ferguson, Murdo
-
Murray, Alexande ...
-
Pliamm, Lew
-
Rombo, Lars
-
Sanmartin Berglu ...
-
David, Marie-Pie ...
-
visa fler...
-
De Schrevel, Nat ...
-
Maschino, Franck
-
Kotb, Shady
-
Olivier, Aurélie
-
Hulstrøm, Veroni ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Hälsovetenskap
-
och Folkhälsovetensk ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Geriatrik
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Annan medicin oc ...
-
och Gerontologi medi ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Mikrobiologi ino ...
- Artiklar i publikationen
-
Vaccine: X
- Av lärosätet
-
Blekinge Tekniska Högskola
-
Lunds universitet
-
Uppsala universitet